Search

Author/Creator Braun, Daniel K

1. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Issue 9993 (8th August 2015)

Authors:
Griffiths, Christopher E M; Reich, Kristian; Lebwohl, Mark; van de Kerkhof, Peter; Paul, Carle; Menter, Alan; Cameron, Gregory S; Erickson, Janelle; Zhang, Lu; Secrest, Roberta J; Ball, Susan; Braun, Daniel K; Osuntokun, Olawale O; Heffernan, Michael P; Nickoloff, Brian J; Papp, Kim
Journal:
Lancet
Issue:
Volume 386:Issue 9993(2015)
Page Start:
541
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Issue 1 (23rd August 2016)

Authors:
Mease, Philip J; van der Heijde, Désirée; Ritchlin, Christopher T; Okada, Masato; Cuchacovich, Raquel S; Shuler, Catherine L; Lin, Chen-Yen; Braun, Daniel K; Lee, Chin H; Gladman, Dafna D
Other Names:
author non-byline.; Barkham N author non-byline.; Bessette L author non-byline.; Alonso R Blanco author non-byline.; Box EJ author non-byline.; Brooks M author non-byline.; Vargas R Burgos author non-byline.; Chandran V author non-byline.; Dhar R author non-byline.; Nebro A Fernandez author non-...
Journal:
Annals of the rheumatic diseases
Issue:
Volume 76:Issue 1(2017)
Page Start:
79
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search